FrancophonIA/ELRC3.0 huggingface dataset:
English: D168Y V36Ac, V36Mc, F43Lc, D168H, E357Kc
Croatian: V36Ac, V36Mc, F43Lc, D168H, E357Kc NS5A M28T
English: Dasabuvir had reduced activity in biochemical assays against NS5B polymerases from HCV genotypes 2a, 2b, 3a and 4a (IC50 values ranging from 900 nM to >20 μM).
Croatian: Biokemijskim testovima dokazana je smanjena aktivnost desabuvira protiv NS5B polimeraza genotipa 2a, 2b, 3a i 4a (raspon vrijednosti IC50 od 900 nM do >20 μM).
English: Among all GT1 subjects who were post liver transplant, 111/114 (97.4%) achieved SVR12; with 2 relapsing post treatment and 1 breakthrough on treatment.
Croatian: Među svim ispitanicima s infekcijom genotipom 1 kojima je transplantirana jetra, njih 111/114 (97,4%) postiglo je SVR12, dok su 2 ispitanika doživjela relaps nakon liječenja, a jedan virološki proboj tijekom liječenja.
English: Ombitasvir treatment-emergent variants M28T, M28V or Q30R in NS5A were observed in 32 subjects.
Croatian: Varijante M28T, M28V ili Q30R nastale u NS5A tijekom liječenja ombitasvirom primijećene su u 32 ispitanika.
English: Note: For laboratory abnormalities refer to Table 4.
Croatian: Napomena: za odstupanja u laboratorijskim vrijednostima vidjeti Tablicu 4.
English: Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir can decrease exposures of medicinal products that are metabolized by CYP2C19 (e.g. lansoprazole, esomeprazole, smephenytoin), which may require dose adjustment/clinical monitoring.
Croatian: Istodobna primjena dasabuvira s ombitasvirom/paritaprevirom/ritonavirom može smanjiti izloženost lijekovima koji se metaboliziraju putem CYP2C19 (npr. lanzoprazol, esomeprazol, s-mefentoin) radi čega može biti potrebna prilagodba doze/klinički nadzor.
English: These ALT elevations were significantly more frequent in the subgroup of subjects who were using ethinyloestradiol -containing medicinal products such as combined oral contraceptives or contraceptive vaginal rings (6 of 25 subjects); (see section 4.3).
Croatian: Povišene razine ALT-a češće su primijećene u podskupini ispitanica koje su primale lijekove koji sadrže etinilestradiol, poput kombiniranih oralnih kontraceptiva ili kontracepcijskih vaginalnih prstenova (kod 6 od ukupno 25 ispitanica) (vidjeti dio 4.3).
English: Patients should be informed that fatigue has been reported during treatment with dasabuvir in combination with ombitasvir/paritaprevir/ritonavir and ribavirin (see section 4.8).
Croatian: Bolesnike je potrebno upozoriti da je tijekom liječenja dasabuvirom u kombinaciji s ombitasvirom/paritaprevirom/ritonavirom i ribavirinom prijavljen umor (vidjeti dio 4.8).
English: PROTON PUMP INHIBITORS Omeprazole
Croatian: INHIBITORI PROTONSKE PUMPE Omeprazol
English: The High Pure system assay had a lower limit of quantification (LLOQ) of 25 IU per mL and the AmpliPrep assay had a LLOQ of 15 IU per mL.
Croatian: Donja granica kvantifikacije (engl. lower limit of quantification, LLOQ) testa za uporabu sa sustavom High Pure System iznosila je 25 IU/ml, dok je LLOQ u testu AmpliPrep iznosio 15 IU/ml.
English: The overall safety profile in HCV-infected transplant recipients who were administered dasabuvir and ombitasvir/paritaprevir/ritonavir and ribavirin (in addition to their immunosuppressant medicinal products) was similar to subjects treated with dasabuvir and ombitasvir/paritaprevir/ritonavir and ribavirin in phase 3 clinical trials, although some adverse reactions were increased in frequency.
Croatian: Ukupan sigurnosni profil u ispitanika s transplantiranom jetrom s infekcijom HCV-om koji su liječeni dasabuvirom i ombitasvirom/paritaprevirom/ritonavirom i ribavirinom (uz imunosupresivne lijekove) bio je sličan onome u ispitanika liječenih dasabuvirom i ombitasvirom/paritaprevirom/ritonavirom i ribavirinom u fazi III kliničkih ispitivanja iako su neke nuspojave imale veću učestalost.
English: Treatment duration 12 weeks
Croatian: Skupina liječena 24 tjedna
English: For a general comment on treatment of HIV co-infected patients, including a discussion on different antiretroviral regimens that may be used, please see section 4.4 (Treatment of HIV co-infected patients) and the Summary of Product Characteristics of ombitasvir/ paritaprevir /ritonavir.
Croatian: Za opće upute o liječenju bolesnika s istodobnom infekcijom HIV-om, uključujući informacije o različitim kombinacijama liječenja, vidjeti dio 4.4 (Liječenje bolesnika s istodobnom infekcijom HIV-om) i sažetak opisa svojstava lijeka ombitasvir/paritaprevir/ritonavir.
English: In biochemical assays, dasabuvir inhibited a panel of genotype 1a and 1b polymerases with a mean IC50 value of 4.2 nM (range 2.2 to 10.7 nM; n=7).
Croatian: U biokemijskim je testovima dasabuvir inhibirao paletu polimeraza genotipa 1a i 1b uz srednju vrijednost IC50 od 4,2 nM (raspon: 2,2 do 10,7 nM; n=7).
English: No genotype 1b infected subjects had treatment-emergent variants in all 3 drug targets.
Croatian: Niti u jednog ispitanika s infekcijom genotipom 1b nisu se tijekom liječenja razvile varijante na ciljnim mjestima svih triju lijekova.
English: In vitro studies show that dasabuvir is not an inhibitor of organic cation transporters (OCT2), organic anion transporters (OAT3), or multidrug and toxin extrusion proteins (MATE1 and MATE2K) at clinically relevant concentrations.
Croatian: Ispitivanja in vitro pokazuju da dasabuvir nije inhibitor prijenosnika organskih kationa (OCT2), prijenosnika organskih aniona (OAT3) ili proteina za izlučivanje više lijekova i toksina (MATE1 i MATE2K) pri klinički značajnim koncentracijama.
English: The pharmacokinetics of dasabuvir with ombitasvir/paritaprevir/ritonavir in paediatric patients has not been investigated (see section 4.2).
Croatian: Nije ispitivana farmakokinetika dasabuvira i ombitasvira/paritaprevira/ritonavira u pedijatrijskih bolesnika (vidjeti dio 4.2).
English: • mitotane
Croatian: • mitotan
English: Tell your doctor or pharmacist before taking Exviera, if you are taking any of the medicines in the table below.
Croatian: Obratite se svom liječniku ili ljekarniku prije nego uzmete lijek Exviera ako uzimate bilo koji od lijekova navedenih u sljedećoj tablici.
English: Number of subjects treated
Croatian: Broj liječenih ispitanika
English: Carisoprodol
Croatian: Karisoprodol
English: Darunavir, dosed 800 mg once daily, if administered at the same time as ombitasvir/paritaprevir/ritonavir, can be used in the absence of extensive PI resistance (darunavir exposure lowered).
Croatian: Darunavir, u dozi od 800 mg jedanput dnevno, ako se primjenjuje u isto vrijeme s ombitasvirom/paritaprevirom/ritonavirom, smije se koristiti ako kod bolesnika nema izražene rezistentnosti na inhibitor proteaze (PI) (smanjena izloženost darunaviru).
English: Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, with dasabuvir 400 mg were evaluated in subjects with mild (CrCl: 60 to 89 ml/min), moderate (CrCl: 30 to 59 ml/min) and severe (CrCl: 15 to 29 ml/min) renal impairment, relative to subjects with normal renal function.
Croatian: Farmakokinetika kombinacije ombitasvira u dozi od 25 mg, paritaprevira u dozi od 150 mg i ritonavira u dozi od 100 mg, s dasabuvirom u dozi od 400 mg, ocijenjena je u ispitanika s blagim (CrCl: 60 do 89 ml/min), umjerenim (CrCl: 30 do 59 ml/min) i teškim (CrCl: 15 do 29 ml/min) oštećenjem funkcije bubrega u odnosu na ispitanike s normalnom funkcijom bubrega.
English: The direction of the arrow indicates the direction of the change in exposures (Cmax, and AUC) in the paritaprevir, ombitasvir, dasabuvir and the co-administered medicinal product (↑= increase more than 20%, ↓ = decrease more than 20%, ↔ = no change or change less than 20%).
Croatian: dasabuviru i istodobno primijenjenom lijeku (↑= povećanje za više od 20%, ↓ = smanjenje za više od 20%, ↔ = nema promjene ili je promjena manja od 20%).
English: Liver transplant recipients
Croatian: Ispitanici s transplantiranom jetrom
English: Hydrocodone (as given in a fixed-dose hydrocodone /paracetamol
Croatian: paracetamol (primijenjen kao fiksna kombinacija hidrokodon/ paracetamol
English: Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir together with medicinal products that are substrates of BCRP may increase plasma concentrations of these transporter substrates, potentially requiring dose adjustment/clinical monitoring.
Croatian: Istodobna primjena dasabuvira s ombitasvirom/paritaprevirom/ritonavirom zajedno s lijekovima koji su supstrati za BCRP može povećati koncentraciju supstrata prijenosnika u plazmi što može potencijalno zahtijevati prilagodbu doze/kliničko praćenje.
English: Pharmacodynamic interactions
Croatian: Farmakodinamičke interakcije
English: Dasabuvir should be used in combination with other medicinal products for the treatment of HCV (see section 5.1).
Croatian: Dasabuvir se mora uzimati u kombinaciji s drugim lijekovima za liječenje virusa hepatitisa C (HCV) (vidjeti dio 5.1).
English: HIV ANTIVIRALS: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Rilpivirine2
Croatian: ANTIVIROTICI ZA LIJEČENJE HIV-a: NENUKLEOZIDNI INHIBITORI REVERZNE TRANSKRIPTAZE Rilpivirin2
English: Dasabuvir is not recommended for administration as monotherapy and must be used in combination with other medicinal products for the treatment of hepatitis C infection (see section 4.2 and 5.1).
Croatian: Dasabuvir se ne preporučuje za primjenu u monoterapiji nego se mora primjenjivati u kombinaciji s drugim lijekovima za liječenje infekcije hepatitisom C (vidjeti dio 4.2 i 5.1).
English: Co-administration of dasabuvir with medicinal products that are strong or moderate enzyme inducers is expected to decrease dasabuvir plasma concentrations and reduce its therapeutic effect (see section 4.5.
Croatian: Pri istodobnoj primjeni dasabuvira s lijekovima koji su snažni ili umjereni induktori enzima očekuje se snižavanje koncentracije dasabuvira u plazmi i smanjenje njegovog terapijskog učinka (vidjeti dio 4.5).
English: How to take
Croatian: Kako uzeti lijek
English: ANTIFUNGALS Ketoconazol e
Croatian: ANTIMIKOTICI Ketokonazo l
English: Interactions between dasabuvir with ombitasvir/paritaprevir/ritonavir and other medicinal products
Croatian: Tablica 2. Interakcije između dasabuvira s ombitasvirom/paritaprevirom/ritonavirom i drugih lijekova
English: Enzalutamid e
Croatian: Enzalutami d
English: A total of 129 subjects were treated, 84 with GT1a, 41 with GT1b, 1 with GT1 other, 3 with GT4 infection.
Croatian: Ukupno je bilo liječeno 129 ispitanika, od kojih je njih 84 imalo infekciju genotipom 1a, 41 infekciju genotipom 1b, 1 infekciju genotipom 1 - ostale, a 3 infekciju genotipom
English: Concomitant use with efavirenz containing regimens is contraindicated (see section 4.3).
Croatian: Istodobna primjena s režimima koji sadrže efavirenz je kontraindicirana (vidjeti dio 4.3).
English: − Tablet film-coating: poly(vinyl alcohol) (E 1203), titanium dioxide (E 171), macrogol (3350), talc (E 553b), iron oxide yellow (E 172), iron oxide red (E 172) and iron oxide black (E 172).
Croatian: Film ovojnica tablete: poli(vinilni alkohol) (E 1203), titanijev dioksid (E 171), makrogol (3350), talk (E 553b), žuti željezov oksid (E 172), crveni željezov oksid (E 172) i crni željezov oksid (E 172).
English: Patients with moderate to severe hepatic impairment (Child-Pugh B or C) (see section 5.2).
Croatian: Bolesnici s umjerenim do teškim oštećenjem funkcije jetre (Child-Pugh stadij B ili C) (vidjeti dio 5.2).
English: Diazepam2 mg single dose
Croatian: Diazepam 2 mg pojedinačna doza
English: If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Exviera.
Croatian: Ako se bilo što od gore navedenoga odnosi na Vas (ili niste sigurni), razgovarajte sa svojim liječnikom ili ljekarnikom prije nego uzmete lijek Exviera.
English: It may not be excluded that the systemic exposure of dabigatran etexilate is increased by dasabuvir due to inhibition of P-gp in the intestine.
Croatian: Ne može se isključiti da dasabuvir povećava sistemsku izloženost dabigatraneteksilatu zbog inhibicije P
English: Recommendations for co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir for a number of medicinal products are provided in Table 2.
Croatian: Preporuke za istodobnu primjenu dasabuvira s ombitasvirom/paritaprevirom/ritonavirom s nizom drugih lijekova nalaze se u Tablici 2.
English: Medicinal products transported by the OATP family Refer to the ombitasvir/paritaprevir/ritonavir Summary of Product Characteristics for details on OATP1B1, OATP1B3 and OATP2B1 substrates (see also Table 2).
Croatian: Vidjeti sažetak opisa svojstava lijeka za ombitasvir/paritaprevir/ritonavir za detalje o supstratima OATP1B1, OATP1B3 kao i OATP2B1(također vidjeti Tablicu 2).
English: Co-administration of dasabuvir with medicinal products that are moderate or strong enzyme inducers is expected to decrease dasabuvir plasma concentrations and reduce its therapeutic effect.
Croatian: Očekuje se da će istodobna primjena dasabuvira s lijekovima koji su umjereni ili snažni induktori enzima smanjiti koncentracije dasabuvira u plazmi i oslabiti njegov terapijski učinak.
English: AbbVie Deutschland GmbH & Co. KG Tel: 00800 222843 33 (gebührenfrei) Tel: +49 (0) 611 / 1720-0
Croatian: KG Tel: 00800 222843 33 (gebührenfrei) Tel: +49 (0) 611 / 1720-0
English: The recommended co-administered medicinal product(s) and treatment duration for dasabuvir combination therapy are provided in Table 1.
Croatian: Preporučeni lijek(ovi) za istodobnu primjenu s dasabuvirom te trajanje kombinirang liječenja navedeni su u Tablici 1.
English: CORAL-I: treatment-naïve or pegIFN + RBV-experienced, GT 1 or GT4 infected, at least 3 months post liver transplant or 12 months post renal transplant
Croatian: CORAL-I: ispitanici s infekcijom genotipom 1 ili 4, prethodno neliječeni ili prethodno liječeni kombinacijom pegIFN + RBV, najmanje 3 mjeseca nakon transplantacije jetre ili 12 mjeseci nakon transplantacije bubrega
English: HCV genotype (GT)
Croatian: Genotip (GT) HCV-a
English: Blood and lymphatic system disorders Common
Croatian: Poremećaji krvi i limfnog sustava često anemija
English: Cross-resistance is expected among NS5A inhibitors, NS3/4A protease inhibitors, and non-nucleoside NS5B inhibitors by class.
Croatian: Očekuje se križna rezistencija između inhibitora NS5A, inhibitora NS3/4A proteaze i nenukleozidnih inhibitora NS5B, prema razredima lijekova.
English: Table 15.
Croatian: Tablica 15.
English: • Each tablet contains 250 mg of dasabuvir (as sodium monohydrate).
Croatian: • Jedna tableta sadrži 250 mg dasabuvira (u obliku natrijeva hidrata).
English: Note: Doses used for dasabuvir + ombitasvir/paritaprevir/ritonavir were: ombitasvir 25 mg paritaprevir 150 mg, ritonavir 100 mg, once daily and dasabuvir 400 mg twice daily or 250 mg twice daily.
Croatian: Napomena: primijenjene doze dasabuvira + ombitasvir/paritaprevir/ritonavir bile su: ombitasvir 25 mg, paritaprevir 150 mg, ritonavir 100 mg, jedanput na dan, te dasabuvir 400 mg dvaput na dan ili 250 mg dvaput na dan.
English: Each carton contains 56 tablets (multipack carton containing 4 inner cartons of 14 tablets).
Croatian: Svaka kutija sadrži 56 tableta (višestruko pakiranje koje sadrži 4 unutarnja pakiranja sa po 14 tableta).
English: randomised, global multicentre, double-blind, placebo-controlled
Croatian: randomizirano, globalno, multicentrično, dvostruko slijepo, placebom kontrolirano ispitivanje
English: Treated subjects had a median age of 51 years (range: 26 to 64); 65.8% were male and 5.3% were Black.
Croatian: Medijan dobi liječenih ispitanika iznosio je 51 godinu (raspon: 26 - 64 godine); 65,8% bili su muškaraci, a
English: Subjects were on a stable HIV-1 antiretroviral therapy (ART) regimen that included ritonavir-boosted atazanavir or raltegravir, dolutegravir (Part 2 only), or darunavir (Part 1b and Part 2 GT4 only)-, co-administered with a backbone of tenofovir plus emtricitabine or lamivudine.
Croatian: Ispitanici su bili na stalnom režimu liječenja antiretroviroticima koji je uključivao ritonavirom pojačan atazanavir ili raltegravir, dolutegravir (samo u 2. dijelu) ili darunavir (u dijelu 1b i 2. dijelu samo kod infekcije genotipom 4), uz istodobnu primjenu terapijske okosnice sastavljene od tenofovira plus emtricitabin ili lamivudin.
English: If ribavirin is co-administered with dasabuvir and ombitasvir/paritaprevir/ritonavir, the contraindications regarding use of ribavirin during pregnancy apply (see also the Summary of Product Characteristics of ribavirin).
Croatian: Ako se ribavirin primjenjuje istodobno s dasabuvirom i ombitasvirom/paritaprevirom/ritonavirom, vrijede kontraindikacije koje se odnose na primjenu ribavirina tijekom trudnoće (vidjeti i sažetak opisa svojstava lijeka za ribavirin).
English: Serious and/or life threatening events have been observed with co-administration of dasabuvir and ombitasvir/paritaprevir/ritonavir with systemic tacrolimus, and a similar risk can be expected with sirolimus and everolimus.
Croatian: Kod istodobne primjene dasabuvira i ombitasvira/paritaprevira/ritonavira sa sistemskim takrolimusom primijećeni su ozbiljni i/ili po život opasni događaji, a sličan se rizik može očekivati i kod primjene sa sirolimusom i everolimusom.
English: Pharmacokinetic steady state for dasabuvir when coadministered with ombitasvir/paritaprevir/ritonavir is achieved after approximately 12 days of dosing.
Croatian: Farmakokinetičko stanje dinamičke ravnoteže za dasabuvir, kad se primjenjuje istodobno s ombitasvirom/paritaprevirom/ritonavirom, postiže se nakon približno 12 dana primjene.
English: Caution should be used in patients with a pre-existing history of depression or psychiatric illness.
Croatian: Potreban je oprez u bolesnika s depresijom ili psihijatrijskom bolešću u anamnezi.
English: Sustained virologic response (SVR) was the primary endpoint to determine the HCV cure rate in the Phase 3 studies and was defined as unquantifiable or undetectable HCV RNA 12 weeks after the end of treatment (SVR12).
Croatian: HCV-a u ispitivanjima faze 3, a definirao se kao razina HCV RNK ispod razine kvantifikacije ili mjerljivosti 12 tjedana nakon završetka liječenja (SVR12).
English: b. Other includes early drug discontinuation not due to virologic failure and missing HCV RNA values in the
Croatian: b. Ostalo uključuje ranu obustavu liječenja, ali ne zbog virološkog neuspjeha i nedostatak podataka o razinama HCV RNK u razdoblju određivanja SVR12.
English: Lopinavir/ritonavir 400/100 mg twice daily or 800/200 mg once daily is contraindicated dasabuvir
Croatian: Lopinavir/ritonavir 400/100 mg dvaput na dan ili 800/200 mg jednaput na dan je kontraindiciran u s dasabuvirom i ombitasvirom/paritaprevir
English: If statin treatment is required during the treatment period, a switch to a reduced dose of pravastatin/rosuvastatin is possible (see section 4.5, Table 2).
Croatian: Ako je liječenje statinima nužno tijekom razdoblja liječenja, moguće je prebacivanje na smanjenu dozu pravastatina/rosuvastatina (vidjeti dio 4.5, Tablica
English: SVR12 for Genotype 1b-infected treatment-naïve subjects without cirrhosis dasabuvir and ombitasvir/paritaprevir/ritonavir for 8 weeks n/N (%)
Croatian: SVR12 za prethodno neliječene ispitanike s infekcijom genotipom 1b, bez ciroze dasabuvir i ombitasvir/paritaprevir/ritonavir tijekom 8 tjedana n/N (%)
English: ↔ em tricitabine
Croatian: u drugom tromjesječju
English: Pharmacokinetics of the combination of dasabuvir 400 mg, with ombitasvir 25 mg, paritaprevir 200 mg, and ritonavir 100 mg were evaluated in subjects with mild (Child-Pugh A), moderate (ChildPugh B) and severe (Child-Pugh C) hepatic impairment, relative to subjects with normal hepatic function.
Croatian: Farmakokinetika kombinacije dasabuvira u dozi od 400 mg s ombitasvirom u dozi od 25 mg, paritaprevira u dozi od 200 mg i ritonavirom u dozi od 100 mg ocijenjena je u ispitanika s blagim (Child-Pugh stadij A), umjerenim (Child-Pugh stadij B) i teškim (Child-Pugh stadij C) oštećenjem funkcije jetre u odnosu na ispitanike s normalnom funkcijom jetre.
English: Although some cases had previous history of depression, psychiatric illness and/or substance abuse, a causal relation with dasabuvir with or without ombitasvir/paritaprevir/ritonavir treatment cannot be excluded.
Croatian: Iako su u nekim slučajevima depresija, psihijatrijska bolest i/ili zlouporaba droge bile prisutne u bolesnikovoj anamnezi, ne može se isključiti uzročna povezanost s liječenjem dasabuvirom s ombitasvirom/paritaprevirom/ritonavirom ili bez njega.
English: Cases of hepatitis B virus (HBV) reactivation, some of them fatal, have been reported during or after treatment with direct-acting antiviral agents.
Croatian: Tijekom ili nakon liječenja direktno djelujućim antiviroticima zabilježeni su slučajevi reaktivacije virusa hepatitisa B (HBV), neki od njih sa smrtnim ishodom.
English: Table 16.
Croatian: Tablica 16.
English: OPIOIDS Methadone
Croatian: OPIOIDI Metadon
English: Table 18.
Croatian: Tablica 18.
English: In Part 1b, SVR12 was achieved by 22/22 (100%) subjects (95% CI: 85.1%, 100%).
Croatian: 22/22 (100%) ispitanika (95% CI: 85,1%; 100%).
English: Theoretically, dasabuvir with ombitasvir/paritaprevir/ritonavir is expected to increase the exposure to pitavastatin and fluvastatin.
Croatian: Teoretski, očekuje se da će dasabuvir s ombitasvirom/paritaprevirom/ritonavirom povećati izloženost pitavastatinu i fluvastatinu.
English: Table 10.
Croatian: Tablica 10.
English: A decrease in alprazolam dose can be considered based on clinical response.
Croatian: Na temelju kliničkog odgovora može se razmotriti smanjenje doze alprazolama.
English: As the incidence of such elevations was 26% among women taking a concomitant ethinyloestradiol-containing medicine, such medicinal products are contraindicated with dasabuvir and ombitasvir/paritaprevir/ritonavir.
Croatian: S obzirom da je incidencija takvih povišenja bila 26% u ispitanica koje su istodobno uzimale lijekove koji sadrže etinilestradiol, ti lijekovi su kontraindicirani uz dasabuvir s ombitasvirom/paritaprevirom/ritonavirom.
English: The safety summary is based on pooled data from phase 2 and 3 clinical trials in subjects who received dasabuvir and ombitasvir/paritaprevir/ritonavir with or without ribavirin.
Croatian: Sažetak sigurnosnog profila temelji se na objedinjenim podacima iz kliničkih ispitivanja faze 2 i 3, u kojima su ispitanici liječeni dasabuvirom i ombitasvirom/paritaprevirom/ritonavirom s ribavirinom ili bez njega.
English: For the use of HIV protease inhibitors other than atazanavir and darunavir refer to the Summary of Product Characteristics of ombitasvir/ paritaprevir /ritonavir.
Croatian: Za korištenje inhibitora proteaze HIV-a osim atazanavira i darunavira pogledajte sažetak opisa svojstava lijeka za ombitasvir /paritaprevir /ritonavir.
English: − Tablet core: microcrystalline cellulose (E 460(i)), lactose monohydrate, copovidone, croscarmellose sodium, colloidal anhydrous silica (E 551), magnesium stearate (E 470b).
Croatian: Jezgra tablete: mikrokristalična celuloza (E 460(i)), laktoza hidrat, kopovidon, umrežena karmelozanatrij, koloidni bezvodni silicijev dioksid (E 551), magnezijev stearat (E 470b).
English: Three interrupted dasabuvir and ombitasvir/paritaprevir/ritonavir for one to seven days, including one on ethinyloestradiol.
Croatian: Tri su bolesnika prekinula uzimati dasabuvir s ombitasvirom/paritaprevirom/ritonavirom na jedan do sedam dana, uključujući jednog na etinilestradiolu.
English: With compensated cirrhosis
Croatian: S kompenziranom cirozom
English: Desmethyl citalopram
Croatian: S-desmetilcitalopram
English: Ombitasvir/paritaprevir/ritonavir with or without dasabuvir was also evaluated without ribavirin in 18 GT1a- and GT4-infected patients; no adverse events of anaemia were seen in these subjects.
Croatian: Ombitasvir/paritaprevir/ritonavir u kombinaciji s dasabuvirom ili bez njega ocjenjivao se i bez istodobne primjene ribavirina u 18 bolesnika s infekcijom genotipom 1a i genotipom 4; u tih ispitanika nisu primijećeni štetni događaji anemije.